Speaking of convenience and tolerability, current GLP-1 medications sold for weight loss take the form of injectables, but oral versions are on the horizon
273 However, in a recently reported study, treatment of dialysis patients with peginterferon alfa-2a (135 g per week) and low-dose ribavirin (200 mg/day) led to an SVR in 29% of HCV monoinfected patients (one-half with genotype 1) and in one-third of those coinfected with HIV
For providers, the key takeaway is clear: GLP-1 patients require early, strategic, multi-depth intervention
Criticism quickly ensued
Ignoring Nausea or Gastrointestinal Symptoms Its normal to experience some side effects early on, but persistent nausea, vomiting, or constipation should not be ignored
Readers considering the use of GHK-Cu for any purpose, especially with injectable formulations or underlying medical conditions, should consult healthcare providers, as quality control can vary in commercial products